Cavernous Sinus Thrombosis in a Patient with Nephrotic Syndrome by Navarro, D et al.
CASE REPORT
Cavernous sinus thrombosis in a patient with nephrotic syndrome
David Navarro1 • Ana Carina Ferreira1 • Helena Viana1 • Fernanda Carvalho1 •
Fernando Nolasco1
Received: 19 December 2016 / Accepted: 6 May 2017
 Japanese Society of Nephrology 2017
Introduction
Nephrotic syndrome (NS) is a glomerular disease charac-
terized by altered permeability of the glomerular capillary
wall to macromolecules. This results in heavy proteinuria,
hypoalbuminemia, hypercholesterolemia, lipiduria, and
edema.
This clinical and laboratory syndrome is a life-threat-
ening disease, and is associated with several complications,
not only related to the disease itself, but also related to its
treatment.
Disease-associated complications include acute kidney
injury, chronic kidney disease, cardiovascular disease,
negative nitrogen balance, infections, endocrine disorders,
and hypercoagulability.
Venous and arterial thromboembolism is a significant
complication of NS, occurring in approximately 27% of the
patients [1]. This represents an 800% increase relatively to
the general population [1, 2]. The pathophysiology of
thrombogenesis in NS is not fully understood, and seems to
be multifactorial [3], depending on the etiology (particu-
larly frequent in membranous nephropathy), serum albu-
min level (most likely when\2 g/dl), previous episodes,
and genetic predisposition [1, 2, 4].
These patients are at an increased risk of deep vein
thrombosis (DVP), renal vein thrombosis (RVP), and pul-
monary embolism (PE). Cerebral venous thrombosis
(CVT) is infrequent, being primarily reported in children
[1, 2].
The authors report a case of a 45-year-old white female
patient admitted with NS and multiple venous thrombosis.
Case report
A 45-year-old Caucasian Portuguese woman, with no sig-
nificant medical history and under no medication, pre-
sented with face and inferior extremities swelling, and pain
in her right calf. She had started amoxicillin and NSAIDs a
few days before, as she was submitted to a dental treat-
ment. She was diagnosed with DVT and admitted to the
hospital, where she stopped the previous medication and
initiated anticoagulation with low-molecular-weight hep-
arin. Even so, she developed sudden shortness of breath,
and after computed tomography angiography, PE was
diagnosed (Fig. 1). She later on complained of persistent
nausea and headache, and an MRI allowed for the diag-
nosis of cavernous sinus thrombosis (CST) (Fig. 2).
The laboratory tests revealed the presence of a nephrotic
syndrome (total protein 4.0 g/dl, serum albumin 1.4 g/dl,
24-h proteinuria quantification 13.8 g/24 h, total choles-
terol 399 mg/dl, and triglycerides 347 mg/dl), with acute
kidney injury (urea 184 mg/dl and serum creatinine
4.4 mg/dl). Apart from a prolonged aPTT and a reduced
anti-thrombin III, the search for thrombophilic, autoim-
munity, thyroid, and hepatic disorders was unremarkable
(Table 1).
Renal biopsy was initially delayed, since the patient
required anticoagulation. She initiated treatment with
prednisolone (oral 1 mg/kg, once daily) and cyclophos-
phamide (oral 1.5 mg/kg, once daily), with significant
clinical and analytical response. After 15 days of therapy,
24-h proteinuria decreased from 13.8 to 0.7 g/24 h. Fol-
lowing renal function recovery and recanalization of the
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cavernous sinus, anticoagulation was temporarily inter-
rupted, and a renal biopsy was performed. Despite the
relatively short period of anticoagulation suspension
(72 h), the patient suffered a suprahepatic veins’
thrombosis.
Renal biopsy diagnosed minimal change disease.
Cyclophosphamide was suspended and prednisolone
maintained in full dose for 8 weeks. After clinical resolu-
tion, the patient was discharged with oral anticoagulation
(with International Normalized Ratio target of 2–3),
tapered prednisolone, a statin, and a low-dose ACE
inhibitor.
The patient achieved a complete remission of NS and
steroids were stopped after 9 months. Anticoagulation was
stopped after 20 months of therapy. After 3 years of fol-
low-up, no relapse of the disease was observed, but a
borderline positive lupus anticoagulant was discovered.
The 12-week later repetition remained borderline. Five
years have passed since the initial hospitalization. During
this period, the patient has been relapse-free, and no further
thromboembolic events have occurred.
Discussion
This is a case of a severe form of NS diagnosed after
several thrombotic events, probably triggered by NSAIDs’
use. Treatment with prednisolone and cyclophosphamide
was started on the grounds that it is the first line therapy for
membranous nephropathy and is second line therapy in
minimal change disease and in segmental focal glomeru-
losclerosis, in cortico-dependent patients. The renal biopsy
revealed minimal change disease, and cyclophosphamide
was suspended. At this time, the patient had a proteinuria
of 0.7 g/24 h and serum albumin 4 g/dl. Even so, the
patient experienced a new thrombotic event due to a 72 h
anticoagulation suspension.
Hypercoagulation is the consequence of an imbalance
between the clotting activator system and the inhibitor
system. The urinary leakage of coagulation regulatory
proteins, such as anti-thrombin III and plasminogen, is
thought to be the main thrombophilic mechanism in the
nephrotic patient, but the increased platelet activation and
elevated fibrinogen and factors V and VIII also seem to
have a role. These aspects are partially counterbalanced by
the increased rate of liver-produced hemostatic proteins,
but the balance is nonetheless shifted towards a hyperco-
agulability state [1, 2, 5–7].
There are other factors that increase the risk of throm-
bosis, specifically advanced age and the severity of
hypoalbuminemia [1, 2]. Indeed, severe hypoalbuminemia
appears to be the most significant biochemical risk factor
for thrombosis [8].
Fig. 1 Computed tomographic pulmonary angiography, showing
segmentar and subsegmentar bilateral pulmonary embolism. R right,
A anterior
Fig. 2 Cranial MRI, showing
cavernous sinus thrombosis.




The thromboembolic events are more likely to occur
within the first few months of disease and during relapses.
While still under debate, it is thought that the high loss of
coagulation factors and acute intravascular volume deple-
tion during these stages of the disease are responsible for
that [1, 2, 8]. DVT of the extremities is the most frequent
thromboembolic event in patients with nephrotic syn-
drome, with RVP also being notoriously frequent [1, 2].
CVT is a rare complication of nephrotic syndrome, and
while uncommon, with an overall incidence of\1.5 per
100,000 annually, it has increasingly been reported, prob-
ably reflecting underdiagnosis [9]. Most cases are located
in the superior sagittal sinus, while deep cerebral venous
system thrombosis accounts for approximately 16% of
cases [10]. Female-gender-related risk factors (pregnancy,
puerperium and oral contraceptives) explain the 3:1
female-to-male ratio in CVT. Women also have a better
prognosis [9]. While there have been reports of CVT in
nephrotic syndrome [11, 12], cavernous sinus thrombosis is
nearly always caused by an infection of the paranasal
sinuses, the orbit, or the face [13]. This is the first report of
a nephrotic syndrome-related cavernous sinus thrombosis,
but it is difficult to exclude the possibility that the dental
treatment at the beginning of the case was partly respon-
sible for the subsequent cavernous sinus thrombosis.
Clinical presentation of CVT can be variable, subtle, and
non-specific, causing delays in diagnosis. Headache is the
most frequent symptom, being present in 89% of patients,
and it is usually the first and sometimes only symptom of
CVT [9, 10]. Nevertheless, most patients present with rapid
neurological deterioration [10]. CST characteristically
manifests with a variable dysfunction of cranial nerves
passing through it (nerves III, IV, V, and VI). All patients
with nephrotic syndrome with neurological complains
should undergo neuroimaging. The most sensitive method
to diagnose CVT is MRI venography. Aside from neu-
roimaging, there is no specific laboratory test for CVT
[9, 10].
There are no randomized trials to guide optimal pro-
phylaxis or therapy of hypercoagulability in NS [3]. In the
non-complicated NS, prophylactic anticoagulation is not
recommended, unless serum albumin is below 2.0 g/dl (or
below 2.8 g/dl in membranous nephropathy) [3]. For
those with thromboembolic events, anticoagulation is
indicated, with some authors suggesting that anti-throm-
bin III concentrate or fresh frozen plasma, in addition to
heparin, might be needed to control the thromboembolic
state [14, 15]. The duration of the therapy is still con-
troversial, but a total of 3–6 months is recommended, and
should be maintained until the provocating illness has
resolved or is in remission [1, 3, 4]. Thrombolysis is
reserved for those with the most severe thromboembolic
disease [1].
In this case, the patient maintained warfarin during
20 months, with good result. While the initial scan was
negative for thrombophilia, it was repeated, given the
number and severity of thrombotic events. A twice positive
borderline lupus anticoagulant test prompts us to think that
there could be another hidden disease, such as antiphos-
pholipid syndrome (APS).
It’s accepted that multiple risk factors can interact to
exceed the thrombotic threshold and thrombosis occurs
when a transient risk factor enters the play. In the current
case, the nephrotic syndrome was the triggering factor. It is
known that borderline positive antiphospholipid test result
confers thrombosis risk [16], so the thrombotic threshold
theory seems to apply. The initial test was negative prob-
ably due to the effect of anticoagulation and urinary loss
Table 1 Investigation blood tests at presentation
Value Reference range Value Reference range
Hemoglobin (g/dl) 14.9 12–16 Anti-cardiolipin: IgG/IgM (RU/ml) 8.3/4.2 \12/\12
Platelets (9109/l) 283 150–400 Anti-b2 glycoprotein IgG/IgM (RU/ml) 2.1/3.5 \20/\20
Prothrombin time (s) 11.1 9.5–13 Lupus anticoagulant ratio 1.06 0.8–1.2
INR 0.9 0.9–1.2 ANA Negative
aPTT (s) 42.7 24.5–35.2 C3 (mg/dl) 135 75–140
Fibrinogen (mg/dl) 369 175–470 C4 (mg/dl) 36.9 10–34
Factor V 115% 50–150 ANCA MPO/PR3 (U/ml) \2/\2 \20/\20
Anti-thrombin III 70% 80–120 AST (SGOT) (U/l) 29 14–36
Protein C 143% 70–140 GGT (U/l) 63 12–43
Protein S 69.3% 53–109 LDH (U/l) 558 313–618
D-dimer (ng/ml) 415 \300 VDRL test Negative –
Homocysteine (lmol/l) 18.03 \15 HIV Negative –
TSH (lUI/ml) 0.83 0.4–4 HCV Negative –
T4L (ng/dl) 1.3 0.8–1.9 HBV Negative –
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due to the nephrotic syndrome [17]. Duration of treatment
is dictated by the presence of a definite APS—whether this
low titer positive result allows for that diagnosis is unclear.
Furthermore, the presence of a transient precipitating factor
advises for a limited duration anticoagulant therapy [18].
As stated previously, most recurrences occur within the
first 6 months of cessation of anticoagulation and the
recurrence risk seems to decline over time [19].
Our patient has now been without anticoagulation for
over 3 years and no clinical event has occurred. In our
understanding, she should only receive thromboprophy-
laxis in high-risk situations, such as surgery or a relapse of
NS.
Conclusion
Thromboembolic disease is a severe complication of NS
and a high degree of suspicion is necessary to identify
some forms of the disease. Our knowledge of the throm-
bophilic mechanisms in the NS is still incomplete, and no
clinically relevant biomarker has yet emerged. Future
studies should hub on the identification of biomarkers to
determine which patients benefit from prophylactic
anticoagulation.
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